Trials / Withdrawn
WithdrawnNCT00801125
Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy
A Phase IV, Open-Label Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate the safety, tolerability and clinical benefit of TYSABRI® (natalizumab) in patients with moderately to severely active Crohn's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | natalizumab |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2010-05-01
- First posted
- 2008-12-03
- Last updated
- 2016-06-16
Source: ClinicalTrials.gov record NCT00801125. Inclusion in this directory is not an endorsement.